CAMILLE N ABBOUD
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology SAINT LOUIS, MO NPI 1316965320
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology MO NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$94,518.24
- Category: General Payments
- Program years: PY2018–2024
- Record count: 98
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,425.86 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $960.86 | 5 |
| Travel and Lodging | $465.00 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,152.17 | 4 |
| GENZYME CORPORATION | $133.49 | 1 |
| Janssen Biotech, Inc. | $121.81 | 1 |
| ABBVIE INC. | $18.39 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078793864 | Janssen Biotech, Inc. | $121.81 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086617815 | Novartis Pharmaceuticals Corporation | $123.70 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086617819 | Novartis Pharmaceuticals Corporation | $563.47 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086617821 | Novartis Pharmaceuticals Corporation | $397.99 | 05/30/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1086617823 | Novartis Pharmaceuticals Corporation | $67.01 | 05/30/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1103163030 | ABBVIE INC. | $18.39 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1139883293 | GENZYME CORPORATION | $133.49 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.